ArticleChest2016
A Case-Control Study Assessing the Impact of Nonventilated Hospital-Acquired Pneumonia on Patient Outcomes.
Article in Chest, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 2 syntheses or guidelines pooled it, 128 citations in OpenAlex.
- Toward standardized outcome reporting in pneumonia: an overview of systematic reviews of antimicrobial therapy.International journal of clinical pharmacy · 2026Pooled it
- Enhanced oral hygiene interventions as a risk mitigation strategy for the prevention of non-ventilator-associated pneumonia: a systematic review and meta-analysis.British dental journal · 2020Pooled it
- Derivation and validation of a nomogram for predicting nonventilator hospital-acquired pneumonia among older hospitalized patients.BMC pulmonary medicine · 2022Trial
- Syndromic Multiplex Polymerase Chain Reaction: The Impact on Microbial Yield in Nonventilator Hospital-Acquired Pneumonia.Open forum infectious diseases · 2026Article
- Development and Validation of a Nomogram for Predicting Sepsis Risk in Patients with Non-Ventilator Hospital-Acquired Pneumonia.Biomedicines · 2026Article
- Surveillance of temporal trends and antimicrobial resistance in nosocomial respiratory pathogens, Switzerland, 2007 to 2024.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- Implementation of an adaptable semi-automated nonventilator hospital-acquired pneumonia (nvHAP) surveillance system in swiss acute care hospitals: a feasibility study.Infection control and hospital epidemiology · 2026Article
- From plan to practice: a structured report on implementation strategies for preventing non-ventilator hospital-acquired pneumonia (nvHAP).Infection control and hospital epidemiology · 2026Article
- Exploratory pharmacokinetic/pharmacodynamic range of tigecycline for balancing treatment effect and safety in hospital-acquired pneumonia: a retrospective cohort study.Frontiers in pharmacology · 2026Article
- Nurses' Views on Barriers to Oral Care in Non-Mechanically Ventilated Patients in the Intensive Care Unit: A Qualitative Study.Nursing in critical care · 2025Article
- Bacteremic nosocomial pneumonia caused by Gram-negative bacilli: results from the nationwide ALARICO study in Italy.Infection · 2025Observational
- Preventability of Hospital Deaths in Patients With Non-Ventilator Hospital-Acquired Pneumonia.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Hospital-acquired respiratory viral infections while applying droplet precautions on-site (DroPS) - prospective observation during the 2019/20 influenza season, Bern, Switzerland.Infection prevention in practice · 2024Article
- Adverse Outcomes of Patients with Non-Ventilator-Associated Hospital-Acquired Pneumonia (nvHAP)-A Single Centre Cohort Study.Infectious disease reports · 2024Article
- Impact of hospital-acquired pneumonia on the Medicare program.Infection control and hospital epidemiology · 2024Article
- In Support of Universal Admission Testing for SARS-CoV-2 During Significant Community Transmission.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Ten Issues to Update in Nosocomial or Hospital-Acquired Pneumonia: An Expert Review.Journal of clinical medicine · 2023Review
- Non-ventilator-associated ICU-acquired pneumonia (NV-ICU-AP) in patients with acute exacerbation of COPD: From the French OUTCOMEREA cohort.Critical care (London, England) · 2023Article
- Positive sputum culture ofChinese medical journal pulmonary and critical care medicine · 2023Article
- Trends in Molecular Diagnosis of Nosocomial Pneumonia Classic PCR vs. Point-of-Care PCR: A Narrative Review.Healthcare (Basel, Switzerland) · 2023Review
Corrections and comments
- Commented on by
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNonventilated hospital-acquired pneumonia (NVHAP) is a serious nosocomial infection that is increasingly attributed to antibiotic-resistant bacteria.
methodsThis is a retrospective case-control study comparing patients with and those without NVHAP from January 1, 2014 to December 31, 2014 at Barnes-Jewish Hospital, a 1,300-bed urban academic medical center in St. Louis, Missouri.
resultsOne hundred seventy-four consecutive patients with NVHAP were enrolled. A random sample of 696 control patients matched by age, sex, race, and hospital admission date were selected from a total of 5,322 potential matched control subjects. NVHAP was pathogen-negative in 98 cases (56.3%). Respiratory viruses were identified in 42 patients (24.1%), gram-negative bacteria were seen in 25 patients (14.4%), and gram-positive bacteria were identified in 20 patients (11.5%). Individuals in whom NVHAP developed were more likely to die (15.5% vs 1.6%; P < .01), to require intensive care (56.3% vs 22.8%; P < .01) or mechanical ventilation (19.0% vs 3.9%; P < 0.01), and to have a longer hospital length of stay (15.9 days [range, 9.8-26.3 days] vs 4.4 days [range, 2.9-7.3 days]; P < 0.01). This case-control study identified a strong association between hospital mortality and NVHAP, with patients who acquired NVHAP having an 8.4 times greater odds of death (95% CI, 5.6-12.5).
conclusionsThe occurrence of NVHAP was associated with significant increases in mortality, the use of intensive care and mechanical ventilation, and hospital length of stay. We also found that respiratory viruses were an important cause of NVHAP. These findings suggest that efforts aimed at the successful prevention of NVHAP could improve patient outcomes and reduce health-care costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.